- Trials with a EudraCT protocol (253)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
253 result(s) found for: Body load.
Displaying page 1 of 13.
EudraCT Number: 2012-002413-19 | Sponsor Protocol Number: GS-US-218-0103 | Start Date*: 2012-10-15 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected with Respiratory Syncytial Virus (RSV-A Me... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001862-56 | Sponsor Protocol Number: 64041575RSV2004 | Start Date*: 2018-01-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (... | |||||||||||||
Medical condition: Respiratory syncytial virus infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000358-26 | Sponsor Protocol Number: BETAF-RED | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer | |||||||||||||
Full Title: Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults. | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001509-25 | Sponsor Protocol Number: 53718678RSV2006 | Start Date*: 2019-08-16 | ||||||||||||||||
Sponsor Name:Janssen Sciences Ireland UC | ||||||||||||||||||
Full Title: A Two-Part Study With a Birth Cohort (Observational Stage) for Early Diagnosis of Respiratory Syncytial Virus (RSV), Followed by an Optional Phase 2a, Randomized, Double-blind, Placebo-controlled S... | ||||||||||||||||||
Medical condition: Acute Respiratory Tract Infection due to RSV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003359-33 | Sponsor Protocol Number: MABS06 | Start Date*: 2023-06-21 | |||||||||||
Sponsor Name:MUMC | |||||||||||||
Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers | |||||||||||||
Medical condition: Mitochondrial myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002106-68 | Sponsor Protocol Number: CTU/2020/354 | Start Date*: 2020-07-16 | |||||||||||
Sponsor Name:University College London Comprehensive Clinical Trial Unit | |||||||||||||
Full Title: Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 | |||||||||||||
Medical condition: SARS-CoV-2 (Corona virus) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001696-22 | Sponsor Protocol Number: 64041575MPN2001 | Start Date*: 2018-06-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine ... | |||||||||||||
Medical condition: Human metapneumovirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Temporarily Halted) PL (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005694-31 | Sponsor Protocol Number: 2012/ADE002 | Start Date*: 2013-07-05 | |||||||||||
Sponsor Name:Adenovir Pharma AB | |||||||||||||
Full Title: Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Mult... | |||||||||||||
Medical condition: Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKC | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001653-40 | Sponsor Protocol Number: 64041575RSV2003 | Start Date*: 2016-12-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Re... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002455-16 | Sponsor Protocol Number: LTGV550-PII-11/06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Laboratoires Théa | |||||||||||||
Full Title: Efficacy and safety of GV 550 in acute adenoviral keratoconjunctivitis | |||||||||||||
Medical condition: acute adenoviral keratoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001641-79 | Sponsor Protocol Number: 64041575RSV2001(ALS-8176-505) | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administer... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003121-17 | Sponsor Protocol Number: DU001 | Start Date*: 2014-09-09 |
Sponsor Name:D.A.S.T. BIOTECH PHARM Ε.Π.Ε. | ||
Full Title: Randomized, double-blind intervention study of efficacy and safety of the product Vioplex-T compared with placebo in patients with open sores (pressure ulcers). | ||
Medical condition: Pressured Ulcers in I & II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003252-24 | Sponsor Protocol Number: 53718678RSV2004 | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Le... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) SE (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002474-30 | Sponsor Protocol Number: 2019-002474-30 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: PERSONALIZED MOLECULAR DRIVEN SURGERY ACCORDING TO BRCA MUTATIONAL STATUS IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS WITH HIGH TUMOR LOAD | |||||||||||||
Medical condition: ADVANCED OVARIAN CARCINOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003797-25 | Sponsor Protocol Number: GH100-013 | Start Date*: 2005-12-09 |
Sponsor Name:ConjuChem, Inc. | ||
Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study to Evaluate the Efficacy and Safety of CJC-1295 administered for 12 weeks in HIV-Infected Patients with HIV-associated Visc... | ||
Medical condition: Patients 18 to 65 years old with HIV-associated visceral obesity, on a stable antiviral regimen for at least 6 weeks, with a viral load ≤1,000 copies/mL and CD4 count ≥200 cells/mm3, a body mass in... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001889-10 | Sponsor Protocol Number: STOIC | Start Date*: 2020-06-02 |
Sponsor Name:University of Oxford, Clinical Trials and Research Governance | ||
Full Title: Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation | ||
Medical condition: COVID 19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2006-006902-27 | Sponsor Protocol Number: ALN-RSV01-105 | Start Date*: 2007-04-18 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety and efficacy of intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with R... | |||||||||||||
Medical condition: Experimentally induced Respiratory Syncytial Virus infection. The experimental infectious dose has been titrated in a previous study in healthy volunteers. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001107-20 | Sponsor Protocol Number: MDT-637-CP-201 | Start Date*: 2013-08-02 | |||||||||||
Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd. | |||||||||||||
Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) | |||||||||||||
Medical condition: RSV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000790-38 | Sponsor Protocol Number: CRSV 604A 2203 | Start Date*: 2008-07-01 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus | ||
Medical condition: infection with respiratory syncytial virus | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003546-16 | Sponsor Protocol Number: 1.2 | Start Date*: 2014-03-20 |
Sponsor Name:Medizinische Universität Wien, Klin. Abt. für Endokrinologie & Stoffwechsel, Universitätsklinik für Innere Medizin III | ||
Full Title: The Link between Obesity And Vitamin D in bariatric patients with omega-loop bypass surgery: a randomized controlled, double-blinded clinical supplementation trial - LOAD | ||
Medical condition: The aim of the study is to increase vitamin D concentrations respectively to keep it on high level by supplementing with cholecalciferol in a different dose regime, and to improve the overall healt... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
